Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)
21.20
+8.42 (65.88%)
NASDAQ · Last Trade: Mar 7th, 8:07 AM EST
Detailed Quote
Previous Close
12.78
Open
21.13
Bid
21.15
Ask
21.23
Day's Range
21.08 - 21.23
52 Week Range
5.635 - 21.23
Volume
78,373,825
Market Cap
1.56B
PE Ratio (TTM)
-20.38
EPS (TTM)
-1.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,964,678
Chart
About Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)
Day One Biopharmaceuticals Inc is a biotechnology company focused on developing innovative therapies for patients with serious diseases, particularly in the field of oncology. The company is dedicated to creating targeted treatments for pediatric and adult patients, with an emphasis on precision medicine that addresses the specific genetic and molecular characteristics of their cancers. By leveraging advanced science and a deep understanding of cancer biology, Day One aims to deliver effective, safe, and impactful therapeutic options, improving the lives of patients facing difficult-to-treat conditions. Read More
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) to Servier for $21.50 per share in cash.
SURESNES, France and BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025.
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time.
BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:00 p.m. EST.
